For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Impairment of acquired in-process research and development intangible assets | - | - | - | 16,514,000 |
| Revenue | - | 0 | - | 0 |
| General and administrative | 2,171,000 | 3,145,000 | 2,546,000 | 2,253,000 |
| Research and development | 3,641,000 | 2,329,000 | 4,887,000 | 5,804,000 |
| Impairment of acquired in-process research and development intangible assets | - | 0 | - | - |
| Total operating expenses | 5,812,000 | 5,474,000 | 7,433,000 | 24,571,000 |
| Loss from operations | -5,812,000 | -5,474,000 | -7,433,000 | -24,571,000 |
| Other income, net | 405,000 | 210,000 | 961,000 | 113,000 |
| Net loss | -5,407,000 | -5,264,000 | -6,472,000 | -24,458,000 |
| Other comprehensive income (gain) foreign currency translation | 10,000 | 27,000 | -1,000 | -153,000 |
| Total comprehensive loss | -5,397,000 | -5,237,000 | -6,473,000 | -24,611,000 |
| Basic EPS | -0.2 | -0.197 | -0.24 | -1.05 |
| Diluted EPS | -0.2 | -0.197 | -0.24 | -1.05 |
| Basic Average Shares | 26,585,258 | 26,650,276 | 26,585,258 | 23,298,455 |
| Diluted Average Shares | 26,585,258 | 26,650,276 | 26,585,258 | 23,298,455 |
Inmune Bio, Inc. (INMB)
Inmune Bio, Inc. (INMB)